Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Clinical Trial of Eribulin Mesylate and the PD-L1 Monoclonal Antibody, Avelumab, in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients

NCT03502681 is registered in ClinicalTrials.gov with Monika Joshi, MD as lead sponsor.

NCT NCT03502681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03502681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Clinical Trial of Eribulin Mesylate and the PD-L1 Monoclonal Antibody, Avelumab, in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
Lead sponsor
Monika Joshi, MD
Phase
Phase 1
Overall status
Terminated
Start date
June 12, 2018
Completion date
October 25, 2019
Enrollment
6 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic urothelial cell cancer